BEN-MAIMON CAROLE
Executive buyerDirector, President and CEO · Larimar Therapeutics, Inc.
Every open-market stock purchase BEN-MAIMON CAROLE has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- LRMRLarimar Therapeutics, Inc.
One purchase totalling $50.0K at an average of $2.77 per share. See all insider buying in LRMR →
Avg price paid$2.77Latest price—Market capUnknown
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving BEN-MAIMON CAROLE or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from BEN-MAIMON CAROLE's Form 4 filings on SEC EDGAR (CIK 1529611) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.